193 related articles for article (PubMed ID: 37999126)
1. Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives.
Malainou CP; Stachika N; Damianou AK; Anastopoulos A; Ploumaki I; Triantafyllou E; Drougkas K; Gomatou G; Kotteas E
Curr Oncol; 2023 Nov; 30(11):9734-9745. PubMed ID: 37999126
[TBL] [Abstract][Full Text] [Related]
2. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
3. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
[TBL] [Abstract][Full Text] [Related]
4. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
Breast J; 2022; 2022():9238804. PubMed ID: 35711896
[TBL] [Abstract][Full Text] [Related]
5. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
6. A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.
Asghari A; Wall K; Gill M; Vecchio ND; Allahbakhsh F; Wu J; Deng N; Zheng WJ; Wu H; Umetani M; Maroufy V
Oncotarget; 2022; 13():600-613. PubMed ID: 35401937
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
[TBL] [Abstract][Full Text] [Related]
8. Distinct invasive patterns in situ between estrogen receptor-positive and triple-negative breast cancer through the intraductal tracking of carbon nanoparticles.
Kuang X; Luo Z; Sun Z; Hu J; Liu J; Kong D; Wang G; Guo L; Luo L; Zheng W; Sun S; Rao Y; Chen C
Int J Cancer; 2023 Sep; 153(5):1067-1079. PubMed ID: 37255230
[TBL] [Abstract][Full Text] [Related]
9. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
13. Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.
Xia S; Lin Q
Technol Cancer Res Treat; 2022; 21():15330338221090351. PubMed ID: 35450488
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
15. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Bianchini G; Pusztai L; Karn T; Iwamoto T; Rody A; Kelly C; Müller V; Schmidt S; Qi Y; Holtrich U; Becker S; Santarpia L; Fasolo A; Del Conte G; Zambetti M; Sotiriou C; Haibe-Kains B; Symmans WF; Gianni L
Breast Cancer Res; 2013; 15(5):R86. PubMed ID: 24060333
[TBL] [Abstract][Full Text] [Related]
16. The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.
Lashen AG; Toss MS; Mongan NP; Green AR; Rakha EA
Cancer; 2023 Apr; 129(8):1183-1194. PubMed ID: 36653923
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer.
Egelston CA; Guo W; Tan J; Avalos C; Simons DL; Lim MH; Huang YJ; Nelson MS; Chowdhury A; Schmolze DB; Yim JH; Kruper L; Melstrom L; Margolin K; Mortimer JE; Yuan Y; Waisman JR; Lee PP
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 35132960
[TBL] [Abstract][Full Text] [Related]
18. Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
Lu C; Yang Y; Lingmei L; Qiujuan H; Qianru G; Lisha Q; Wenfeng C; Yun N; Peisen Z
Breast Cancer Res Treat; 2023 Jan; 197(1):71-82. PubMed ID: 36334189
[TBL] [Abstract][Full Text] [Related]
19. Utility of TRPS-1 immunohistochemistry in diagnosis of metastatic breast carcinoma in cytology specimens.
Abdelwahed M; Yurtsever N; Savant D; Karam P; Gimenez C; Das K; Sheikh-Fayyaz S; Khutti S
J Am Soc Cytopathol; 2022; 11(6):345-351. PubMed ID: 36055933
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling.
Hamel KM; King CT; Cavalier MB; Liimatta KQ; Rozanski GL; King TA; Lam M; Bingham GC; Byrne CE; Xing D; Collins-Burow BM; Burow ME; Belgodere JA; Bratton MR; Bunnell BA; Martin EC
Stem Cells Dev; 2022 Oct; 31(19-20):604-620. PubMed ID: 35579936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
